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A major risk factor contributing to increased mortality and morbidity
following traumatic brain injury (TBI) is oedema formation. Recent ef-
forts by our laboratory, and others, have concentrated on establishing the
mechanisms associated with oedema formation following brain injury,
and developing appropriate pharmacologic interventional therapies. Our
own studies to date have shown that neurogenic inflammation is a major
contributor to brain oedema formation. Attenuation of the neurogenic
inflammation, either by preventing release of the neuropeptides or block-
ing substance P receptor binding, profoundly inhibited these events. We
propose that pharmacologic intervention targeting neurogenic inflamma-
tion may be a promising strategy for the management of posttraumatic
oedema.
Introduction
Traumatic brain injury (TBI) is the biggest killer of individuals under
44 years of age in industrialized countries. In younger victims of TBI,
almost 50% of death and disability has been reported to be associated
with uncontrolled brain swelling (Feickert et al., 1999), while in all age
groups combined, 50% of all deaths following severe brain injury can be
accounted for by this factor (Marmarou, 2003). It therefore comes as no
surprise that reduction of brain oedema and swelling is one of the major
objectives in the clinical management of TBI.
Approaches to clinical oedema management are widely varied and
include hyperventilation, cranial decompression, osmotic agents, and
pharmacological interventions such as barbiturates and steroids (Reilly,
1997). The success of these approaches, and in particular the pharmaco-
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logical interventions, has been limited largely due to the fact that they do
not address the mechanisms associated with oedema formation. In part,
this has been because the mechanisms have remained obscure. However,
over the past few years, significant progress has been made in under-
standing oedema formation, including the contributions of both vasogenic
and cytotoxic oedema to posttraumatic brain swelling.
Oedema after TBI
A number of studies in different models have now demonstrated that
TBI is followed by two phases of oedema (Marmarou, 2003). The first
is a transient vasogenic phase that increases the extracellular water con-
centration. The blood brain barrier is permeable during this phase. There-
after, there is an intracellular accumulation of water that persists for
several days. In the absence of any blood brain barrier opening, the
second phase of oedema is thought to largely represent cytotoxic oedema.
Significantly, Marmarou and colleagues (Beaumont et al., 2000) have
reported that the initial vasogenic oedema is permissive for the formation
of the later cytotoxic phase. This raises the possibility that inhibiting the
initial vasogenic component of posttraumatic brain oedema may also at-
tenuate the later formation of cytotoxic oedema.
Vasogenic oedema
Vasogenic oedema is characterised by disruption of the blood brain
barrier, and this increased permeability is central to oedema development.
A variety of factors that cause disruption have been identified including
bradykinin, histamine, arachidonic acid, leukotrienes, interleukins, and
tumour necrosis factor, amongst others (Abbott, 2000). Many of these
factors are inflammatory mediators, supporting the concept that tissue
oedema constitutes the major marker of an inflammatory process. One
inflammatory process that has received little attention in the CNS, but has
long been recognised as a major factor in peripheral tissue oedema, is
neurogenic inflammation (Campos and Calixto, 2000).
Neurogenic inflammation is a neurally elicited reaction that has typical
characteristics of an inflammatory reaction including vasodilation, protein
extravasation and tissue swelling. Studies in peripheral tissue have dem-
onstrated that neurogenic inflammation is the result of the stimulation of
C-fibres, which causes the release of neuropeptides (Woie et al., 1993).
Although a number of neuropeptides have been implicated in this proc-
ess, it is generally accepted that substance P (SP) is primarily associated
with an increase in microvascular permeability leading to oedema forma-
tion (Campos and Calixto, 2000). Virtually all blood vessels of the body
are surrounded by sensory nerve fibres that contain these neuropeptides.
Cerebral arteries, in particular, appear to receive a dense supply of these
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neurones, and it is therefore consistent that these neurones have a role as
mediators of the inflammatory process.
Neurogenic inflammation after TBI
Our recent studies have concentrated on characterising the role of
neurogenic inflammation after TBI. We have shown that prior depletion
of neuropeptides using the vanilloid agonist, capsaicin, profoundly inhib-
its the development of vasogenic oedema formation after TBI (Nimmo et
al., 2004). There was also an attenuation of oedema formation at later
time points, consistent with the concept that vasogenic oedema is permis-
sive for later cytotoxic oedema. Since substance P has been identified as
the neuropeptide that is primarily responsible for oedema formation fol-
lowing peripheral tissue injury (Campos and Calixto, 2000), and the
neurokinin-1 (NK1) receptor has been identified as being critical to this
development, we subsequently examined whether administration of an
NK1 antagonist after TBI could attenuate oedema formation. When the
NK1 antagonist, n-acetyl-tryptophan, was administered 30 min after the
traumatic event, there was an attenuation of blood brain barrier perme-
ability and a significant reduction in oedema formation. This reduction in
oedema formation was accompanied by a significant improvement in
functional outcome. Our results are consistent with the hypothesis that
neurogenic inflammation plays an integral role in the increased perme-
ability of the blood brain barrier after TBI and the associated develop-
ment of vasogenic oedema.
Mechanisms
Figure 1 illustrates the mechanisms whereby administration of an NK1
antagonist can potentially attenuate disruption of the blood brain barrier
and inhibit vasogenic oedema formation after TBI. TBI induces the re-
lease of neuropeptides including substance P, calcitonin gene related peptide
(CGRP), neurokinin A and neurokinin B, amongst others. This release
can be stimulated by a number of factors including acidosis or vanilloid
agonists. Once released, neurokinin A and B as well as substance P can
bind to neurokinin receptors on the target cell. While substance P can
bind to all three receptors, it has a much higher affinity for the NK1
receptor. Activation of the neurokinin receptors stimulates the formation
of eicosanoids via the cyclo-oxygenase pathway (Hartung et al., 1988),
nitric oxide (Sterner-Kock et al., 1999) and the kinin-kallikrein pathway
(Campos and Calixto, 2000), all of which are inflammatory mediators
that can disrupt the blood brain barrier. The release of bradykinin can
also activate further neuropeptide release by binding to bradykinin receptors
on the neurone (Campos and Calixto, 2000). Substance P can also stimu-
late the production of serotonin and histamine by mast cells, with the
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latter also activating further release of the neuropeptides. Finally, it should
be noted that CGRP has been shown to potentiate the actions of sub-
stance P, although its co-release is not a mandatory requirement for sub-
stance P induced neurogenic inflammation (Brain et al., 1995).
Other pharmacological interventions
A number of compounds have been shown to inhibit oedema forma-
tion following TBI, although the mechanisms associated with this effect
have been largely unknown. Having identified the critical role that neu-
rogenic inflammation may play in vasogenic oedema formation, some of
the actions of these successful therapies may be rationalized in terms of
actions on neurogenic inflammation. For example, bradykinin B2 receptor
antagonists have been shown to reduce oedema formation following ex-
Figure 1. Mechanisms associated with the development of neurogenic inflammation
after TBI.
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perimental TBI (Stover et al., 2000). This action may be mediated through
effects on neurogenic inflammation since bradykinin B2 receptor antago-
nists have been reported to reduce neurogenic inflammation (Linardi et
al., 2000). Similarly, a number of studies with progesterone and its metabolites
have shown that the neurosteroid attenuates oedema formation after TBI
(Wright et al., 2001). What is significant is that neurosteroids block neurogenic
inflammation, particularly progesterone and allopregnanolone (Limmroth
et al., 1996). Similarly, cannabinoids have been shown to reduce oedema
formation following TBI (McCarron et al., 2003). However, cannabinoids
are known agonists of the vanilloid receptor (Grotenhermen, 2004), and
both agonists and antagonists of the vanilloid receptor have been found
capable of preventing the development of neurogenic inflammation or
even abolishing an ongoing inflammatory process (Linardi et al., 2000).
Conclusion
We have identified that neurogenic inflammation, and particularly
substance P, plays a critical role in the development of oedema formation
following TBI. Inhibition of neuropeptide release, or inhibition of the
NK1 receptor, significantly attenuates the posttraumatic opening of the
blood brain barrier and subsequent development of vasogenic oedema. A
number of pharmacological agents that have previously been shown to
attenuate posttraumatic oedema have an interaction with the pathways
associated with neurogenic inflammation, and may thus mediate their
effects via modulation of this pathway.
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